BTK and B-cell chronic lymphocytic leukemia: For example, therapy with the covalent, orally bioavailable BTK inhibitor ibrutinib, one of the first targeted agents in CLL, leads to a rapid shrinkage of tumor mass in lymphoid organs, caused in part by the redistribution of CLL cells from the tissue into the bloodstream.